** Hong Kong shares of China's biopharmaceutical group Zai
Lab Ltd 9688.HK jump 23.9 to HK$16.30, on track for the
biggest one-day pct rise since January 2023
** Stock hit the highest since March 14 on the second
session of gain; second biggest pct gainer on Hang Seng
Composite Index .HSCI
** The drugmaker says its net product revenue amounted to
$87.1 mln for the first quarter, up 39% YoY, with strong balance
sheet having a cash position of $750.8 mln as end-March
** Co says first quarter net loss was $53.5 mln, compared to
net loss of $49.1 mln in the same period in 2023
** Josh Smiley, president, says Zai Lab is entering a period
of robust growth with the launch of VYVGART at end of last year
and multiple new products and indications expected to launch
near-term
** Hong Kong's healthcare index .HSCIH surges 3.1%, Hang
Seng Composite Index .HSCI rises 1.3%, Hang Seng Index .HSI
adds 1.1%
** Hong Kong-listed shares down 25.4% YTD, and U.S. stock
ZLAB.O down 39.4% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))